欧盟HMA药品数据库(European Union HMA Authorisation of Medicines DataBase)
MR编号
SE/H/0918/004
药品名称
Numeta G13E
活性成分
Alanine 4.66 g
Arginine 4.89 g
Aspartic acid 3.5 g
Calcium chloride dihydrate 3.45 g
Cysteine 1.1 g
Glucose monohydrate 550.0 g
Glutamic acid 5.83 g
Glycine 2.33 g
Histidine 2.21 g
Isoleucine 3.9 g
leucine 5.83 g
Lysine 6.41 g
Magnesium acetate tetrahydrate 0.63 g
Methionine 1.4 g
Ornithine 1.45 g
Phenylalanine 2.45 g
Potassium acetate 3.83 g
Proline 1.75 g
Serine 2.33 g
SODIUM GLYCEROPHOSPHATE hydrate 6.15 g
Taurine 0.35 g
Threonine 2.16 g
Tryptophan 1.17 g
Tyrosine 0.45 g
Valine 4.43 g
剂型
Emulsion for infusion
上市许可持有人
Baxter Medical AB Sweden
参考成员国 - 产品名称
Sweden (SE)
互认成员国 - 产品名称
Germany (DE)
Numeta G 13 % E
Denmark (DK)
Numeta G13E
Netherlands (NL)
Luxembourg (LU)
United Kingdom (Northern Ireland) (XI)
Ireland (IE)
Austria (AT)
Numeta G 13 % E Emulsion zur Infusion
France (FR)
Spain (ES)
Portugal (PT)
Italy (IT)
Greece (GR)
NUMETA® PRETERM
Norway (NO)
Numeta G13E
Finland (FI)
Poland (PL)
NUMETA G13% E Preterm
Czechia (CZ)
Numeta G13%E
Malta (MT)
Belgium (BE)
Numetzah G13%E émulsion pour perfusion
许可日期
2016/03/15
最近更新日期
2024/10/23
药物ATC编码
B05BA10 combinations
申请类型
TypeLevel1:
Line Extension
TypeLevel2:
Additional Strength/Form
TypeLevel3:
Fixed combination Art 10b Dir 2001/83/EC
TypeLevel4:
Chemical Substance
TypeLevel5:
Prescription Only
附件文件下载
Final PL
|
Final PL
Final SPC
|
Final SPC
PubAR
|
PAR
PubAR Summary
|
PAR Summary
市场状态
Positive
©2006-2025
Drugfuture
->
European Union HMA Authorisation of Medicines DataBase